Longeveron (NASDAQ:LGVN) Price Target Cut to $6.00 by Analysts at Maxim Group

Longeveron (NASDAQ:LGVN) had its target price trimmed by Maxim Group from $15.00 to $6.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $10.00 price objective on shares of Longeveron in a research report on Thursday, August 15th.

Longeveron Stock Performance

NASDAQ LGVN opened at $2.28 on Tuesday. The stock has a market capitalization of $14.48 million, a P/E ratio of -0.24 and a beta of 0.43. Longeveron has a 52 week low of $0.77 and a 52 week high of $35.60. The stock has a fifty day moving average of $2.68 and a 200-day moving average of $2.81.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Longeveron stock. Renaissance Technologies LLC purchased a new stake in Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 146,700 shares of the company’s stock, valued at approximately $236,000. Renaissance Technologies LLC owned 2.31% of Longeveron as of its most recent SEC filing. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.